Weekly Recap

Acadia Halts Phase 3 Pimavanserin Trial, Ofatumumab Superior In MS, Satralizumab Shines in NMOSD at ECTRIMS 2019

ByNeurologyLive® Staff

September 14th 2019

Neurology News Network for the week ending September 14, 2019.

MS Immunization Guidelines, Prognostic Value of NfL in ALS, the Future of Focused Ultrasound

ByNeurologyLive® Staff

September 7th 2019

Neurology News Network for the week ending September 7, 2019.

Istradefylline OK'd for Parkinson, RimabotulinumtoxinB Approved for Chronic Sialorrhea, Dementia in Chronic Truamatic Encephalopathy

ByNeurologyLive® Staff

August 31st 2019

Neurology News Network for the week ending August 31, 2019.

FDA Rejects Duchenne Muscular Dystrophy Drug Golodirsen, Pfizer Recalls Acute Migraine Treatment Relpax, Alzheimer Disease Update

ByNeurologyLive® Staff

August 24th 2019

Neurology News Network for the week ending August 24, 2019.

Impact of Caregiver Depression on Patients With Dementia, CAG Repeat Length Predicts Huntington Disease Decline, Novel Oral CBD Formulation Effective in Epilepsy

ByNeurologyLive® Staff

August 17th 2019

Neurology News Network for the week ending August 17, 2019.

Zolgensma Gene Therapy Data Manipulation, GRF6019 Phase 2 Results in Mild to Moderate Alzheimer, Mind Moments Podcast

ByNeurologyLive® Staff

August 10th 2019

Neurology News Network for the week ending August 10, 2019.

Tic Suppression Ability Predicts Future Symptom Outcomes, Wearable-Detected Gait Changes Predict Parkinson Disease, Early MRI Scans Predict Relapse-Onset Multiple Sclerosis

ByNeurologyLive® Staff

August 3rd 2019

Neurology News Network for the week ending August 3, 2019.

Highlights From the 2019 American Headache Society Annual Scientific Meeting

ByNeurologyLive® Staff

July 24th 2019

This week’s edition features highlights from NeurologyLive’s coverage of the American Headache Society’s annual scientific meeting.

Parkinson Disease Gene Therapy PR001 Granted Fast Track Designation, Telerehabilitation Similar to In-Clinic Rehab for Stroke, New Therapeutic Technologies In Epilepsy

ByNeurologyLive® Staff

July 13th 2019

Neurology News Network for the week ending July 13, 2019.

Nusinersen Shows Long-Term SMA Success, Positive Data for an Investigational DMD Therapy, Zogenix to Resubmit Fenfluramine NDA

ByNeurologyLive® Staff

July 6th 2019

Neurology News Network for the week ending July 6, 2019.

Perampanel Monotherapy Promotes Seizure Freedom, Intranasal Midazolam Rapidly Effective, Safe Alternative in Status Epilepticus, Sleep Disorders and Epilepsy

ByNeurologyLive® Staff

June 29th 2019

Neurology News Network for the week ending June 29, 2019.

Solriamfetol Receives Schedule IV Designation for EDS in Narcolepsy, OSA, ABO-202 Gene Therapy Granted Fast Track Designation for Batten Disease, NfL Shows Multi-disease Usefulness

ByNeurologyLive® Staff

June 22nd 2019

Neurology News Network for the week ending June 22, 2019.

ILAE MRI Recommendations, CPAP in OSA and MCI, Lemborexant Positive for Insomnia

ByNeurologyLive® Staff

June 15th 2019

Neurology News Network for the week ending June 15, 2019.

FDA Approves Galcanezumab for Episodic Cluster Headache, FDA Clears ReStore Exo-Suit for Stroke Rehabilitation, Alzheimer Disease May Be Influenced by LDL-C Levels

ByNeurologyLive® Staff

June 8th 2019

Neurology News Network for the week ending June 8, 2019.

FDA Approves Zolgensma for Spinal Muscular Atrophy, Nerivio Migra Device Granted De Novo Clearance for Migraine, Cladribine Reduces MRI Lesions Across Subgroups in ORACLE-MS Study

ByNeurologyLive® Staff

June 1st 2019

Neurology News Network for the week ending June 1, 2019.

FDA OKs Atlas Stent System, Wearables in Epilepsy Monitoring, and ASA Policy Statement on Stroke Care Systems

ByNeurologyLive® Staff

May 25th 2019

Neurology News Network for the week ending May 25, 2019.

New Guideline for Tourette Syndrome, Tic Disorders, FDA Approves sBLA for IncobotulinumtoxinA for Blepharospasm, Gaboxadol Shows Clinical Benefit in Angelman Syndrome

ByNeurologyLive® Staff

May 18th 2019

Neurology News Network for the week ending May 18, 2019.

Inebilizumab for NMOSD, New Acute Migraine Clinical Trial End Points, Eptinezumab's Pending BLA for Migraine Prevention

ByNeurologyLive® Staff

April 27th 2019

Neurology News Network for the week ending April 27, 2019.

Exome Panel Promising for Diagnosing Epilepsy, Pamrevlumab for Duchenne Muscular Dystrophy Receives Orphan Drug Designation, Riluzole NDA Accepted for ALS

ByNeurologyLive® Staff

April 20th 2019

Neurology News Network for the week of April 20, 2019.

Guidelines for Pediatric Migraine Clinical Trial Design Released, FDA Grants AMT-130 Fast Track Designation for Huntington Disease, ZX008 Receives RFL for Dravet Syndrome

ByNeurologyLive® Staff

April 13th 2019

Neurology News Network for the week of April 13, 2019.

Clardibine Approved for Relapsing, Secondary Progressive MS, Cervella Cranial Electrotherapy Approved for Insomnia, and Management of Stroke With Tandem Occlusion

ByNeurologyLive® Staff

April 6th 2019

Neurology News Network for the week of April 6, 2019.

Siponimod Approved for SPMS, AVP-786 Phase 3 Results for Treatment of Agitation in Alzheimer-Related Dementia, and Mobile Technology for Care of Parkinson Disease

ByNeurologyLive® Staff

March 30th 2019

Neurology News Network for the week of March 30, 2019.

Quality of Life is Predictive of DBS Outcomes in Early Parkinson, Lack of Approved Therapies for MS Symptoms, and Ubrogepant for Acute Treatment of Migraine in Adults

ByNeurologyLive® Staff

March 23rd 2019

Neurology News Network for the week of March 22, 2019.

NDA Accepted for SRP-4053 for DMD, MPRI 2.0 Differentiates Parkinson and Progressive Supranuclear Palsy, and Young Donor Plasma Infusion Warning

ByNeurologyLive® Staff

February 23rd 2019

Neurology News Network for the week of February 23, 2019.

Patients with Parkinson at Greater Risk for Dementia After DBS Implant, a Novel ALS Diagnostic Index, Preliminary IGNITE-DMD Trial Findings

ByNeurologyLive® Staff

February 16th 2019

Neurology News Network for the week of February 14, 2019.

SPRINT-MIND Trial Results, Alemtuzumab and Rituximab Safe for MS, CAP-1002 for Duchenne Muscular Dystrophy

ByNeurologyLive® Staff

February 2nd 2019

Neurology News Network for the week of February 2, 2019.

Ocrelizumab Compared to Other DMTs, Effects of Lemborexant on Next-Day Driving, BHV-3241 Gets FDA OK for Clinical Trial

ByNeurologyLive® Staff

January 26th 2019

Neurology News Network for the week of January 26, 2019.

AHS Statement on CGRP Inhibitors, NDA Submitted for Lemborexant, Dabigatran Assessed in Alzheimer

ByNeurologyLive® Staff

January 19th 2019

Neurology News Network for the week of January 19, 2019.

Fumarate Bioequivalent for MS, Embrace Smartband Approval, Alzheimer Biomarkers Identified, Long-Term Perampanel Data

ByNeurologyLive® Staff

January 12th 2019

Neurology News Network for the week of January 12, 2019.

Solriamfetol PDUFA Date Pushed, Recognizing Parkinson Disease, Chronic Migraine Peer Exchange Program

ByNeurologyLive® Staff

January 5th 2019

Neurology News Network for the week of January 5, 2019.

Weekly Recap

Acadia Halts Phase 3 Pimavanserin Trial, Ofatumumab Superior In MS, Satralizumab Shines in NMOSD at ECTRIMS 2019

MS Immunization Guidelines, Prognostic Value of NfL in ALS, the Future of Focused Ultrasound

Istradefylline OK'd for Parkinson, RimabotulinumtoxinB Approved for Chronic Sialorrhea, Dementia in Chronic Truamatic Encephalopathy

FDA Rejects Duchenne Muscular Dystrophy Drug Golodirsen, Pfizer Recalls Acute Migraine Treatment Relpax, Alzheimer Disease Update

Impact of Caregiver Depression on Patients With Dementia, CAG Repeat Length Predicts Huntington Disease Decline, Novel Oral CBD Formulation Effective in Epilepsy

Zolgensma Gene Therapy Data Manipulation, GRF6019 Phase 2 Results in Mild to Moderate Alzheimer, Mind Moments Podcast

Tic Suppression Ability Predicts Future Symptom Outcomes, Wearable-Detected Gait Changes Predict Parkinson Disease, Early MRI Scans Predict Relapse-Onset Multiple Sclerosis

Highlights From the 2019 American Headache Society Annual Scientific Meeting

Parkinson Disease Gene Therapy PR001 Granted Fast Track Designation, Telerehabilitation Similar to In-Clinic Rehab for Stroke, New Therapeutic Technologies In Epilepsy

Nusinersen Shows Long-Term SMA Success, Positive Data for an Investigational DMD Therapy, Zogenix to Resubmit Fenfluramine NDA

Perampanel Monotherapy Promotes Seizure Freedom, Intranasal Midazolam Rapidly Effective, Safe Alternative in Status Epilepticus, Sleep Disorders and Epilepsy

Solriamfetol Receives Schedule IV Designation for EDS in Narcolepsy, OSA, ABO-202 Gene Therapy Granted Fast Track Designation for Batten Disease, NfL Shows Multi-disease Usefulness

ILAE MRI Recommendations, CPAP in OSA and MCI, Lemborexant Positive for Insomnia

FDA Approves Galcanezumab for Episodic Cluster Headache, FDA Clears ReStore Exo-Suit for Stroke Rehabilitation, Alzheimer Disease May Be Influenced by LDL-C Levels

FDA Approves Zolgensma for Spinal Muscular Atrophy, Nerivio Migra Device Granted De Novo Clearance for Migraine, Cladribine Reduces MRI Lesions Across Subgroups in ORACLE-MS Study

FDA OKs Atlas Stent System, Wearables in Epilepsy Monitoring, and ASA Policy Statement on Stroke Care Systems

New Guideline for Tourette Syndrome, Tic Disorders, FDA Approves sBLA for IncobotulinumtoxinA for Blepharospasm, Gaboxadol Shows Clinical Benefit in Angelman Syndrome

Inebilizumab for NMOSD, New Acute Migraine Clinical Trial End Points, Eptinezumab's Pending BLA for Migraine Prevention

Exome Panel Promising for Diagnosing Epilepsy, Pamrevlumab for Duchenne Muscular Dystrophy Receives Orphan Drug Designation, Riluzole NDA Accepted for ALS

Guidelines for Pediatric Migraine Clinical Trial Design Released, FDA Grants AMT-130 Fast Track Designation for Huntington Disease, ZX008 Receives RFL for Dravet Syndrome

Clardibine Approved for Relapsing, Secondary Progressive MS, Cervella Cranial Electrotherapy Approved for Insomnia, and Management of Stroke With Tandem Occlusion

Siponimod Approved for SPMS, AVP-786 Phase 3 Results for Treatment of Agitation in Alzheimer-Related Dementia, and Mobile Technology for Care of Parkinson Disease

Quality of Life is Predictive of DBS Outcomes in Early Parkinson, Lack of Approved Therapies for MS Symptoms, and Ubrogepant for Acute Treatment of Migraine in Adults

NDA Accepted for SRP-4053 for DMD, MPRI 2.0 Differentiates Parkinson and Progressive Supranuclear Palsy, and Young Donor Plasma Infusion Warning

Patients with Parkinson at Greater Risk for Dementia After DBS Implant, a Novel ALS Diagnostic Index, Preliminary IGNITE-DMD Trial Findings

SPRINT-MIND Trial Results, Alemtuzumab and Rituximab Safe for MS, CAP-1002 for Duchenne Muscular Dystrophy

Ocrelizumab Compared to Other DMTs, Effects of Lemborexant on Next-Day Driving, BHV-3241 Gets FDA OK for Clinical Trial

AHS Statement on CGRP Inhibitors, NDA Submitted for Lemborexant, Dabigatran Assessed in Alzheimer

Fumarate Bioequivalent for MS, Embrace Smartband Approval, Alzheimer Biomarkers Identified, Long-Term Perampanel Data

Solriamfetol PDUFA Date Pushed, Recognizing Parkinson Disease, Chronic Migraine Peer Exchange Program

Trending on NeurologyLive

MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne

Expanding the Alzheimer Drug Development Pipeline

DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point

NeurologyLive® Friday 5 — September 12, 2025

Shared Decision-Making and Ethics in Complex Neurology Clinical Research: Paul Ford, PhD